AGENのPER（株価収益率）は？

Agenus Inc（AGEN）は現在PER 3.16倍で取引されています。

AGENのROE（自己資本利益率）は？

Agenus IncのROEは-29.20%です。

AGENの配当利回りは？

Agenus Incの配当利回りは0.00%です。

AGENの品質スコア（Quality Score）は？

当社のAIはAGENの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

AGENは今が買い時ですか？

当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

AGENはどのセクターに属しますか？

Agenus IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

AGEN (NASDAQ) 株価分析 | AGENUS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

AGEN AI Analysis Summary

Our AI summary for AGEN: Agenus Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.16, ROE of -29.20%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

AGEN

Agenus Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 8.30

0.48 (6.14%) Day Change

Watchlist Portfolio Compare Chart

3.16

P/E

-0.64

D/E

-29.2%

ROE

34.7%

ROA

0.00%

Div Yield

-0.07

PEG

AGENUS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.30 Price 0.48 (6.14%) Day Change	NEWS SCORE: N/A

AGEN, ファンダメンタルスコアはok ( ファンダメンタル = 69) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

63%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	1764
Magic Formula Rank by ROE	1764
Magic Formula Rank by ROIC	95 GOOD
Price	8.30
PBV / Sector	-1.43 / 44,022.72
Earning Per Share	1.65

PE / Sector	3.16 / 19.17 GREAT
PEG or PE/Growth / Sector	-0.07 / 1.24
Average 1M Daily Value	66.41 M
Average 1W Daily Value	15.43 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	52.16 / 98.24 GREAT
NPM Average (%) / Sector	-109.82 / -1,697.63
NPM Change Average (%) / Sector	12,900.95 / 5,097.97 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	34.65 / 185,260.96 GREAT
ROA Average (%) / Sector	-39.44 / 36,684.70
ROA Change Average (%) / Sector	17,052.64 / 422,221.66 GOOD
ROE (%) / Sector	-29.20 / 243,762.23
ROE Average (%) / Sector	121.37 / 48,758.47 GREAT
ROE Change Average (%) / Sector	17,133.27 / 424,968.10 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

登録情報

Analyze Date	2026-08-05 07:59:47
Symbol	AGEN
Name	AGENUS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	41.64 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	325.64 / 9,586.08

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305

Phone: 781 674 4400

Website: https://www.agenusbio.com

Employees: 81

Sector: Healthcare >> Biotechnology

Description: Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.